揭示了Cmaxf2因子的潜力,应用于试点生物可用性/生物等价性研究 - - 一个用帕佐帕尼布制药的案例研究
Sara Carolina Henriques1,2, Ana Leblanc1, Sérgio Simões3,4
1BlueClinical Ltd., Senhora da Hora, 4460-439 Matosinhos, Portugal.
Pharmaceutics
|January 8, 2025
概括
在试点研究中,f2因子为评估生物等价性的传统方法提供了一个有希望的替代方案. 这种方法有助于减少不确定性,并指导进行更大规模的关键试验的决策,即使具有高可变性.
科学领域:
- 药理动力学 药理动力学
- 药物开发 药物开发
- 生物等价性研究 生物等价性研究
背景情况:
- 试点研究是药物开发中的关键守门策略,用于评估新配方和参考产品之间的生物等价性.
- 小型试点研究对变异性高度敏感,导致对全面的关键试验的决策不确定性.
- 目前的平均生物等效统计方法可能不足以用于小型,可变的试点研究.
研究的目的:
- 建议和评估f2因子作为试点生物等价性试验中平均生物等价性方法的替代方案.
- 减轻试点研究中关于最大观测度 (Cmax) 的结论中的不确定性.
- 评估f2因子对生物等效结果的预测潜力.
主要方法:
- 将f2因子方法应用于试点生物等效试验中的药理动力学数据.
- 利用了帕佐帕尼布200毫克和400毫克配方的数据.
- 将f2因子预测与大规模关键研究的结果进行了比较.
主要成果:
- f2因子成功地证明了在预测生物等价性方面的潜力,尽管样本大小小小,人体内变异性很高.
- 使用f2因子进行的积极预测得到了随后的全尺寸枢纽研究结果的验证.
- f2因子在驾试验生物等效试验中固有的高个体内变异性方面被证明是有效的.
结论:
- f2因子作为试点生物等价性研究的有希望的替代方法.
- 这种方法可以显著减少关键生物等价性试验决策过程中的不确定性.
- 实施f2因子可以通过提供更可靠的早期生物等价性评估来优化资源分配.
相关概念视频
Bioavailability: Overview
2.7K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
2.7K
Bioequivalence: Overview
918
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
918
Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH
1.0K
Drug absorption within the gastrointestinal (GI) tract is a complex process influenced by several critical factors, including the site pH, the drug's dissociation constant (pKa), and the drug's lipophilicity. The GI tract exhibits a pH gradient, with an acidic environment in the stomach and a more alkaline environment in the small intestine. This pH variation directly affects the ionization state of drugs.
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
1.0K
Factors Influencing Bioavailability: First-Pass Elimination
6.1K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
6.1K
Factors Influencing Drug Absorption: Drug Dissolution
408
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
408
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
80
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
80


